Shuttle Pharmaceuticals Holdings (Shuttle Pharmaceuticals Holdings) Interest Expense : $-2.39 Mil (TTM As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Shuttle Pharmaceuticals Holdings Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Shuttle Pharmaceuticals Holdings's interest expense for the three months ended in Mar. 2024 was $ -0.50 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.39 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Shuttle Pharmaceuticals Holdings's Operating Income for the three months ended in Mar. 2024 was $ -1.39 Mil. Shuttle Pharmaceuticals Holdings's Interest Expense for the three months ended in Mar. 2024 was $ -0.50 Mil. Shuttle Pharmaceuticals Holdings did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Shuttle Pharmaceuticals Holdings Interest Expense Historical Data

The historical data trend for Shuttle Pharmaceuticals Holdings's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shuttle Pharmaceuticals Holdings Interest Expense Chart

Shuttle Pharmaceuticals Holdings Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Interest Expense

-0.04

-0.05

-0.97

-2.49

Shuttle Pharmaceuticals Holdings Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial									-0.60	-0.73	-0.62	-0.53	-0.50

Shuttle Pharmaceuticals Holdings Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.39 Mil.

Shuttle Pharmaceuticals Holdings (NAS:SHPH) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Shuttle Pharmaceuticals Holdings's Interest Expense for the three months ended in Mar. 2024 was $-0.50 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-1.39 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $0.29 Mil.

Shuttle Pharmaceuticals Holdings's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Shuttle Pharmaceuticals Holdings did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Shuttle Pharmaceuticals Holdings (Shuttle Pharmaceuticals Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shuttle Pharmaceuticals Holdings Inc (NAS:SHPH) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

One Research Court, Suite 450, Rockville, MD, USA, 20850

Website

https://www.shuttlepharma.com

Shuttle Pharmaceuticals Holdings Inc is a clinical stage pharmaceutical company leveraging our proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments by leveraging insights into the pillars of cancer therapy: surgery, radiation therapy, chemotherapy, and immunotherapy.

Executives

Milton Brown	director	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Bette Jacobs	director	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., 1 RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Peter Dritschilo	officer: President and COO	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., SUITE 450, ROCKVILLE MD 20850
Anatoly Dritschilo	director, 10 percent owner, officer: CEO and Chairman	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Tyvin Rich	officer: Chief Medical Officer	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Mira Jung	officer: Chief Scientific Officer	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Hoek Michael Vander	officer: Chief Financial Officer	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., SUITE 450, ROCKVILLE MD 20850
Steven M Richards	director	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
William Adkins	director	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Joshua Schafer	director	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Chris Senanayake	director	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850